Brief: Cann Group Announces Preliminary Results From Their Phase 3 Clinical Trial
Jan 19 (Reuters) - Cann Group Ltd CAN.AX :
* EXPECTS TRIAL RESULTS WILL DELAY SUBMISSION OF
REGISTRATION
APPLICATION TO THERAPEUTIC GOODS ADMINISTRATION FOR THIS
INDICATION
* PRELIMINARY VIEW OF ANALYSIS OF PRIMARY END-POINTS HAVE
NOT
SHOWN A STATISTICALLY SUPERIOR RESPONSE COMPARED TO PLACEBO FOR
SATIPHARM
Source text for Eikon: ID:nASX6Mz404
Further company coverage: CAN.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cann
See all newsBrief: Cann Group Posts Q1 Revenue A$3.45 Million
Brief: Cann Group Increases Private Credit Loan Facility By A$2 Million
Brief: Cann Group Says Mike Ryan To Assume Role Of Interim Exec Chair
Brief: Cann Group Anticipates FY2026 Revenue Of A$9.2-A$10 Million
Brief: Cann Group Posts Profit For Half-Year A$26.4 Million